SCHEMBL4503545

SCHEMBL4503545

COCCOc1ccccc1C(C(N)=O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
HTT P42858 1/20 0.43
HTR1A P08908 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
MAPT P10636 1/20 0.41
ALDH1A1 P00352 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HPGD P15428 1/20 0.40
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.39
DRD2 P14416 1/20 0.39
DRD1 P21728 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4504332 0.93 KDM4E (0.43) LMNAKMT2AMEN1HTTHTR1A
SCHEMBL4509859 0.93 LMNA (0.42) LMNAKMT2AMEN1HTTHTR1A
SCHEMBL4504292 0.84 IDO1 (0.51) LMNAKMT2AMEN1HTTL3MBTL1
SCHEMBL2086063 0.77 TAAR1 (0.46) KMT2AMEN1L3MBTL1HPGDKDM4E
SCHEMBL24977625 0.74 KDM4E (0.43) LMNAKMT2AMEN1HTTL3MBTL1
SCHEMBL10224215 0.72 L3MBTL1 (0.58) LMNAKMT2AMEN1HTTHTR1A
SCHEMBL845057 0.71 CYP1A2 (0.48) LMNAKMT2AMEN1L3MBTL1MAPT
SCHEMBL23835432 0.71 LMNA (0.67) LMNAKMT2AMEN1HTTHTR1A
SCHEMBL9336726 0.71 KMT2A (0.53) KMT2AMEN1HTTL3MBTL1ALDH1A1
SCHEMBL24978136 0.70 KDM4E (0.42) LMNAKMT2AMEN1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233920-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-09-17 US claimed
EP-1907359-A2 3,5-SUBSTITUTED PIPERIDINE DERIVATIVES EFFECTIVE ON RENIN-RELATED DISORDERS Novartis AG (CH) 2008-04-09 EP claimed
WO-2007006534-A2 PIPERIDINE DERIVATIVES USEFUL IN THE DIAGNOSTIC AND THERAPEUTIC TREATMENT OF DISEASES DEPENDING ON RENIN ACTIVITY NOVARTIS AG (CH) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233920-A1 ORGANIC COMPOUNDS REN, ACE, AGTR1 LMNA 2165/4885KMT2A 3192/4885MEN1 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.